Home > Insider Trading > Filing (0001562180-23-004503)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1517022	Akebia Therapeutics Inc.	AKBA	Pharmaceutical Preparations (2834)	208756903

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1669737	Michel Dahan	C/O Akebia Therapeutics, Inc. 245 First Street Cambridge MA 02142	Svp, Chief Operating Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-05-24	200,000	$0.00	669,515	No	4	A	Direct
Common Stock	Disposition	2023-05-25	95,478	$1.22	574,037	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to buy)	Acquisiton	2023-05-24	200,000	$0.00	200,000	$0.41

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
200,000		2032-05-12	No	4	A	Direct

Footnotes

As previously disclosed, in May 2022, the Reporting Person was granted performance-based restricted stock units ("PSUs") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest upon the closing of a significant transaction as defined in the award agreement. On May 24, 2023, the Company entered into a License Agreement, which transaction qualified as a significant transaction and closed on May 24, 2023. As a result, all of the PSUs vested on May 24, 2023
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of all of the PSUs.
As previously disclosed, in May 2022, the Reporting Person was granted performance-based options (the "Options") pursuant to the Issuer's 2014 Incentive Plan, as amended. The Options vest upon the closing of a significant transaction as defined in the award agreements. On May 24, 2023, the Company entered into a License Agreement, which transaction qualified as a significant transaction and closed on May 24, 2023. As a result, all of the shares subject to the Option vested on May 24, 2023.